Stockreport

Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors [Yahoo! Finance]

Nuvation Bio Inc. Class A  (NUVB) 
PDF NEW YORK, March 14, 2024 BUSINESS WIRE )--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developin [Read more]